Definitive Healthcare (NASDAQ:DH) Issues FY 2026 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 0.180-0.200 for the period, compared to the consensus EPS estimate of 0.160. The company issued revenue guidance of $220.0 million-$222.0 million, compared to the consensus revenue estimate of $223.6 million. Definitive Healthcare also updated its Q3 2026 guidance to 0.040-0.050 EPS.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DH shares. Bank of America reiterated an “underperform” rating and set a $0.70 price target on shares of Definitive Healthcare in a report on Monday, June 29th. Zacks Research upgraded shares of Definitive Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 28th. Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a report on Sunday, July 26th. Robert W. Baird set a $1.10 target price on Definitive Healthcare in a research note on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Definitive Healthcare in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat, Definitive Healthcare has an average rating of “Reduce” and a consensus target price of $1.88.

Definitive Healthcare Price Performance

DH stock opened at $0.70 on Tuesday. Definitive Healthcare has a 1 year low of $0.62 and a 1 year high of $4.35. The company has a market cap of $73.86 million, a P/E ratio of -0.43, a PEG ratio of 11.51 and a beta of 1.35. The firm has a 50-day moving average of $0.77 and a 200 day moving average of $1.11. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.75 and a quick ratio of 1.75.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Monday, August 10th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.01. Definitive Healthcare had a positive return on equity of 4.04% and a negative net margin of 76.04%.The business had revenue of $55.20 million for the quarter, compared to analysts’ expectations of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. On average, sell-side analysts forecast that Definitive Healthcare will post 0.04 EPS for the current year.

Trending Headlines about Definitive Healthcare

Here are the key news stories impacting Definitive Healthcare this week:

• Positive Sentiment: Definitive Healthcare reported second-quarter 2026 adjusted earnings of $0.05 per share, exceeding the $0.04 analyst consensus. Full-year 2026 EPS guidance of $0.18–$0.20 also came in above the $0.16 consensus, suggesting better-than-expected earnings profitability. Definitive Healthcare Q2 Earnings Surpass Estimates
• Positive Sentiment: Management’s full-year EPS outlook was raised or set above current expectations, while third-quarter EPS guidance of $0.04–$0.05 brackets consensus at $0.04. Definitive Healthcare Reports Second-Quarter Results
• Neutral Sentiment: Second-quarter revenue totaled $55.2 million, broadly close to—but slightly below—the $55.47 million consensus estimate. Earnings declined from $0.07 per share a year earlier, indicating that the quarterly beat was modest. Definitive Healthcare Q2 2026 Earnings Call Transcript
• Negative Sentiment: Revenue guidance is below Wall Street expectations: third-quarter revenue is projected at $54.0 million–$55.0 million versus a $55.5 million consensus, while full-year revenue guidance of $220 million–$222 million trails the $223.6 million consensus. This suggests slower near-term growth and is likely the main source of investor pressure. Definitive Healthcare Reports Second-Quarter Results
• Negative Sentiment: The company continues to report a deeply negative net margin of approximately 76%, reinforcing concerns about overall profitability despite positive EPS and return on equity.

Hedge Funds Weigh In On Definitive Healthcare

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new position in Definitive Healthcare during the second quarter valued at $32,000. Schonfeld Strategic Advisors LLC bought a new position in shares of Definitive Healthcare in the 4th quarter worth about $35,000. HRT Financial LP purchased a new position in Definitive Healthcare during the 4th quarter valued at about $47,000. ExodusPoint Capital Management LP purchased a new position in Definitive Healthcare during the 4th quarter valued at about $47,000. Finally, Bayesian Capital Management LP purchased a new position in Definitive Healthcare during the 2nd quarter valued at about $55,000. Institutional investors own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.